Menopause Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Menopause Treatment Market is Segmented By Treatment(Hormonal Treatment, Estrogen, Progesterone), By Combination(Non-Hormonal Treatment, Anti-Depressants, Others), By Distribution Channel(Hospital Pharmacies, Online Stores, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Menopause Treatment Market Outlook

Menopause Treatment Market is expected to grow at a CAGR of 8.8% during the forecasting period 2023-2030.

Menopause refers to the end of a woman's menstrual cycle. The term describes any changes women go through just before or after they stop having their period, marking the end of their reproductive years. Menopause requires no medical treatment. Instead, treatments focus on relieving signs and symptoms and preventing or managing Combination conditions with ageing.

Menopause Treatment Market Scope

To Know More Download Sample

Menopause Treatment Market Dynamics

The rise in the geriatric population and the increasing rate of menopause is expected to drive the market. Development in drugs, especially the advancement in hormonal drugs, is expected to fuel the market growth in the forecast period.

The increasing rate of menopause is expected to drive the global menopause treatment market.

Ageing changes the female reproductive system, mainly due to varying hormone levels. One clear sign of ageing occurs when menstrual periods stop permanently. This is known as menopause. Menopause is a normal part of a woman's ageing process. Most women experience menopause around age 50, though it can occur before that age. The usual age range is 45 to 55. More precisely, 55% of people aged 60+ are women, and the percentage rises with age. 64% of the 80+ group of people and 82% of centenarians are women.

For instance, below age 30 yr, 0.3 per cent of the women were in natural menopause compared to 1.3 per cent in the age group of 30-34 yr; 4.8 per cent in the age group of 35-39 yr; 20.2 per cent in the age group of 40-44 yr and 49.1 per cent in the age group of 45-49 yr. According to the U.S. Census Bureau, about 43 million women in the U.S in menopause.

Development in drugs, especially the advancement in hormonal drugs, is expected to fuel the market growth in the forecast period.

Menopause hormone therapy (MHT) is most efficient for the hormonal treatment of climacteric syndrome symptoms and the efficient prevention of long-term estrogen deficiency. The vaginal administration of low doses of estrogen is a therapy of choice for the treatment, prevention of urogenital atrophy and its consequences. The hormone therapy of choice in early menopausal transition is gestagen substitution, levonorgestrel intrauterine system (LNG-IUS), or low-dose monophasic contraception in women. For instance, the FDA approved the first bioidentical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause.

Women who suffer from hot flashes due to menopause may have a new treatment option. The Food and Drug Administration (FDA) approved the oral prescription medication Bijuva (estradiol and progesterone) on October 29, 2018. Bijuva contains bioidentical estradiol and progesterone. "Bioidentical" means the substances were made in a lab but are chemically identical to the hormones women naturally produce.

Lack of health care facilities and awareness is expected to hamper the global menopause treatment market.

Gynecology has always been an area that has tried to understand and assist women in their entirety. Traditionally, the field has focused much of its research and clinical efforts on understanding normal puberty and pregnancy besides pathologic conditions. With the advent of the ageing society, the area needs to quickly understand the average older woman.

For decades, menopause treatment has been dominated by prescription drugs, such as hormone replacement therapy (HRT). The available options for women who can't or choose not to use HRT are typically ineffective over-the-counter medication or simply toughing it out. The failure to effectively invest in women's health and reproductive research, along with the gap in gender representation at the medical school faculty level, has resulted in a poorer understanding of the treatment of menopause. For instance, according to a study carried by Johns Hopkins University, only 20% of OB-GYN residencies cover menopause, and 80% of medical residents are "barely comfortable" discussing it with patients or treating it.

COVID-19 Impact Analysis On Menopause Treatment Market

The regulation and expression of angiotensin-converting enzyme 2 (ACE2) are required for SARS-CoV-2 to enter the cell. 17-oestradiol increases angiotensin-converting enzyme-2 (ACE2) expression and activity, and the alternative signalling pathway of Ang II via the angiotensin II receptor type II (AT2R) and the Mas receptor are more dominant in the female sex than male sex. Perhaps a hint to explain why women have a higher infection risk. Because the dominant female hormone, oestradiol, has immune-modulatory properties that are likely to protect against virus infections, the same hormonal milieu plays a significant role in protecting women in terms of morbidity and mortality. Premenopausal women may be more vulnerable to infection (and thus have higher infection rates) because their economic circumstances are often less favourable, with less opportunity for home office work due to jobs requiring mandatory attendance. Hence, all these factors increase, the chances of women getting infected with COVID-19 are expected to impact the market growth.

Menopause Treatment Market Segment Analysis

The hormonal treatment segment is expected to dominate the global menopause treatment market.

Hormone replacement therapy (HRT) helps to balance estrogen and progesterone levels during or near menopause. Some types of HRT contain both progesterone and estrogen, while some have only estrogen. Sometimes they include testosterone. Hormone treatment helps to address a range of issues. The right combination and dosage of the hormones will depend on prescribing this form of therapy to relieve hot flashes and other menopausal symptoms; estrogen is the most effective treatment available.

For instance, FDA recommends women use hormone therapies that they approve. Hormone therapies approved by FDA are evaluated for safety and effectiveness. Many marketed products called "bioidentical hormones" are compounded drugs, which are not FDA-approved. FDA does not have evidence that compounded "bioidentical hormones" are safe and effective or safer or more effective than FDA-approved hormone therapy. For instance, on October 29, 2018, the FDA approved the first bioidentical hormone therapy combination of estradiol and progesterone for menopausal vasomotor symptoms.

Menopause Treatment Market Geographical Analysis

North America region is expected to hold the largest market share in the global menopause treatment market.

With a sound healthcare system, R&D, and an increasing menopause rate, this region is expected to dominate the market. In the United States, approximately 1.3 million women hit menopausal age each year. It typically begins between the ages of 51 and 52. However, about 5% of women experience early menopause between the ages of 40 and 45. Additionally, 1% of women experience premature menopause before the age of 40 due to permanent ovarian failure associated with sex chromosome abnormalities. The market growth in this region is expected to fuel by increasing drug approvals for menopause treatment.

For instance, U.S. health regulators approved Pfizer Inc. (U.S.) 's menopause drug Duavee, intended to reduce hot flashes with fewer side effects than older hormone-replacement therapies.

Menopause Treatment Market Competitive Landscape

The global menopause treatment market is highly competitive with the increasing rate of menopause in women, company's product launches, acquisitions, and company mergers.

Some of the primary critical players in the global menopause treatment market are Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Allergan, Novartis AG, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Novavax, Inc., Noven Pharmaceuticals, Duchesnay USA Inc.

Bayer Pharmaceuticals

Overview: Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. It is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. The Pharmaceuticals Division of Bayer focuses on prescription products for women's healthcare, cardiology, oncology, hematology, and ophthalmology. Its division comprises the Radiology Business Unit, which markets contrast-enhanced diagnostic imaging equipment and the necessary contrast agents.

Product Portfolio: The company has a drug in the pipeline to treat symptoms associated with menopause. For instance, the company's pipeline drug NT-814 is an orally administered, non-hormonal, potent and selective small-molecule dual antagonist of the neurokinin-1 and 3 receptors. NT-814 treats vasomotor symptoms by modulating a group of estrogen-sensitive neurons in the hypothalamus of the brain (the KNDy neurons), which become hyperactive in menopausal women due to a lack of estrogen and disrupt body heat control mechanisms, resulting in debilitating vasomotor symptoms of hot flashes and night sweats.

Critical Development: On August 4, 2020, Bayer acquired the UK-based biotech KaNDy Therapeutics Ltd. to expand its drug development pipeline in women's healthcare. KaNDy Therapeutics Ltd. completed the NT-814 clinical trials to treat menopausal symptoms such as hot flashes and night sweats.